 Shares of PTC Therapeutics Inc. PTCT, -10.87 were down 10.1 in trading on Wednesday morning, the day after the company said enrollment in a Phase 2 clinical trial for its Huntingtons disease treatment candidate has been paused. PTC told investors on Tuesday night that the Food and Drug Administration had requested additional information about the study. 